Tumor vasculature as target for therapeutic intervention

Bibliography

• Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61(5):759-67
   PubMed Web of Science ®Google Scholar
• Croce CM. Oncogenes and cancer. N Engl J Med 2008;358(5):502-11
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407(6801):249-57
   PubMed Web of Science ®Google Scholar
• Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9(6):653-60
   PubMed Web of Science ®Google Scholar
• Hillen F, Griffioen AW. Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev 2007;26(3-4):489-502
   PubMed Web of Science ®Google Scholar
• Qu B, Guo L, Ma J, Lv Y. Antiangiogenesis therapy might have the unintended effect of promoting tumor metastasis by increasing an alternative circulatory system. Med Hypotheses 2010;74(2):360-1
   PubMed Web of Science ®Google Scholar
• Benjamin LE, Golijanin D, Itin A, Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103(2):159-65
   PubMed Web of Science ®Google Scholar
• Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005;15(1):102-11
   PubMed Web of Science ®Google Scholar
• Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005;5(6):436-46
   PubMed Web of Science ®Google Scholar
• Less JR, Skalak TC, Sevick EM, Jain RK. Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res 1991;51(1):265-73
   PubMed Web of Science ®Google Scholar
• Tozer GM, Ameer-Beg SM, Baker J, Intravital imaging of tumour vascular networks using multi-photon fluorescence microscopy. Adv Drug Deliv Rev 2005;57(1):135-52
   PubMed Web of Science ®Google Scholar
• Baish JW, Jain RK. Fractals and cancer. Cancer Res 2000;60(14):3683-8
   PubMed Web of Science ®Google Scholar
• Hashizume H, Baluk P, Morikawa S, Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000;156(4):1363-80
   PubMed Web of Science ®Google Scholar
• McDonald DM, Foss AJ. Endothelial cells of tumor vessels: abnormal but not absent. Cancer Metastasis Rev 2000;19(1-2):109-20
   PubMed Web of Science ®Google Scholar
• Hobbs SK, Monsky WL, Yuan F, Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 1998;95(8):4607-12
   PubMed Web of Science ®Google Scholar
• Jain RK, Munn LL, Fukumura D. Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer 2002;2(4):266-76
   PubMed Web of Science ®Google Scholar
• Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer 2002;2(2):83-90
   PubMed Web of Science ®Google Scholar
• Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438(7070):932-6
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21):1182-6
   PubMed Web of Science ®Google Scholar
• Ingber D, Fujita T, Kishimoto S, Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990;348(6301):555-7
   PubMed Web of Science ®Google Scholar
• Seaman S, Stevens J, Yang MY, Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007;11(6):539-54
   PubMed Web of Science ®Google Scholar
• Mueller MM, Fusenig NE. Friends or foes? Bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004;4(11):839-49
   PubMed Web of Science ®Google Scholar
• Ronnov-Jessen L, Petersen OW, Bissell MJ. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev 1996;76(1):69-125
   PubMed Web of Science ®Google Scholar
• Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003;3(6):422-33
   PubMed Web of Science ®Google Scholar
• Morikawa S, Baluk P, Kaidoh T, Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002;160(3):985-1000
   PubMed Web of Science ®Google Scholar
• Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6(5):392-401
   PubMed Web of Science ®Google Scholar
• Haviv I, Polyak K, Qiu W, Origin of carcinoma associated fibroblasts. Cell Cycle 2009;8(4):589-95
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454(7203):436-44
   PubMed Web of Science ®Google Scholar
• Kundu JK, Surh YJ. Inflammation: gearing the journey to cancer. Mutat Res 2008;659(1-2):15-30
   PubMed Web of Science ®Google Scholar
• Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124(2):263-6
   PubMed Web of Science ®Google Scholar
• Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66(2):605-12
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706):58-62
   PubMed Web of Science ®Google Scholar
• Jain RK. Molecular regulation of vessel maturation. Nat Med 2003;9(6):685-93
   PubMed Web of Science ®Google Scholar
• Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3(6):401-10
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9(6):669-76
   PubMed Web of Science ®Google Scholar
• Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005;69(Suppl 3):4-10
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23(5):1011-27
   PubMed Web of Science ®Google Scholar
• Brown LF, Detmar M, Claffey K, Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. Exs 1997;79:233-69
   PubMedGoogle Scholar
• Hansen-Algenstaedt N, Stoll BR, Padera TP, Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy. Cancer Res 2000;60(16):4556-60
   PubMed Web of Science ®Google Scholar
• Relf M, LeJeune S, Scott PA, Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57(5):963-9
   PubMed Web of Science ®Google Scholar
• Eliceiri BP, Cheresh DA. The role of alpha-v integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 1999;103(9):1227-30
   PubMed Web of Science ®Google Scholar
• Aplin AE, Howe A, Alahari SK, Juliano RL. Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol Rev 1998;50(2):197-263
   PubMed Web of Science ®Google Scholar
• Felding-Habermann B, Mueller BM, Romerdahl CA, Cheresh DA. Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. J Clin Invest 1992;89(6):2018-22
   PubMed Web of Science ®Google Scholar
• Moschos SJ, Drogowski LM, Reppert SL, Kirkwood JM. Integrins and cancer. Oncology (Williston Park) 2007;21(9 Suppl 3):13-20
   PubMedGoogle Scholar
• Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994;264(5158):569-71
   PubMed Web of Science ®Google Scholar
• McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med 2003;9(6):713-25
   PubMed Web of Science ®Google Scholar
• Brooks PC, Stromblad S, Klemke R, Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995;96(4):1815-22
   PubMed Web of Science ®Google Scholar
• Brooks PC, Montgomery AM, Rosenfeld M, Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79(7):1157-64
   PubMed Web of Science ®Google Scholar
• Bader BL, Rayburn H, Crowley D, Hynes RO. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell 1998;95(4):507-19
   PubMed Web of Science ®Google Scholar
• Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 2005;65(10):3967-79
   PubMed Web of Science ®Google Scholar
• Sund M, Xie L, Kalluri R. The contribution of vascular basement membranes and extracellular matrix to the mechanics of tumor angiogenesis. APMIS 2004;112(7-8):450-62
   PubMed Web of Science ®Google Scholar
• Ribatti D. Endogenous inhibitors of angiogenesis A historical review. Leuk Res 2009;33(5):638-44
   PubMed Web of Science ®Google Scholar
• Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 1990;9(3):267-82
   PubMed Web of Science ®Google Scholar
• Denekamp J. Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer 1982;45(1):136-9
   PubMed Web of Science ®Google Scholar
• Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438(7070):967-74
   PubMed Web of Science ®Google Scholar
• Rosen LS. Angiogenesis inhibition in solid tumors. Cancer J 2001;7(Suppl 3):S120-8
   PubMedGoogle Scholar
• Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4(6):423-36
   PubMed Web of Science ®Google Scholar
• Salsbury AJ, Burrage K, Hellmann K. Inhibition of metastatic spread by I.C.R.F. 159: selective deletion of a malignant characteristic. Br Med J 1970;4(5731):344-6
   PubMed Web of Science ®Google Scholar
• Le Serve AW, Hellmann K. Metastases and the normalization of tumour blood vessels by ICRF 159: a new type of drug action. Br Med J 1972;1(5800):597-601
   PubMed Web of Science ®Google Scholar
• Hellmann K. Dynamics of tumour angiogenesis: effect of razoxane-induced growth rate slowdown. Clin Exp Metastasis 2003;20(2):95-102
   PubMed Web of Science ®Google Scholar
• Rybak SM, Sanovich E, Hollingshead MG, ‘Vasocrine’ formation of tumor cell-lined vascular spaces: implications for rational design of antiangiogenic therapies. Cancer Res 2003;63(11):2812-19
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7(9):987-9
   PubMed Web of Science ®Google Scholar
• Wildiers H, Guetens G, De Boeck G, Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003;88(12):1979-86
   PubMed Web of Science ®Google Scholar
• Lee CG, Heijn M, di Tomaso E, Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000;60(19):5565-70
   PubMed Web of Science ®Google Scholar
• Duda DG, Batchelor TT, Willett CG, Jain RK. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med 2007;13(6):223-30
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Ricotta R, Cerea G, Rationale and clinical results of multi-target treatments in oncology. Int J Biol Markers 2007;22(1 Suppl 4):S77-87
   PubMed Web of Science ®Google Scholar
• Willett CG, Duda DG, di Tomaso E, Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. Nat Clin Pract Oncol 2007;4(5):316-21
   PubMedGoogle Scholar
• Creech O Jr, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958;148(4):616-32
   PubMed Web of Science ®Google Scholar
• Benckhuijsen C, Kroon BB, van Geel AN, Wieberdink J. Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 1988;14(2):157-63
   PubMedGoogle Scholar
• Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992;10:411-52
   PubMed Web of Science ®Google Scholar
• Watanabe N, Niitsu Y, Umeno H, Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res 1988;48(8):2179-83
   PubMed Web of Science ®Google Scholar
• Ten Hagen TL, Van Der Veen AH, Nooijen PT, Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats. Int J Cancer 2000;87(6):829-37
   PubMed Web of Science ®Google Scholar
• Seynhaeve AL, Hoving S, Schipper D, Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response. Cancer Res 2007;67(19):9455-62
   PubMed Web of Science ®Google Scholar
• Kim DW, Andres ML, Li J, Liposome-encapsulated tumor necrosis factor-alpha enhances the effects of radiation against human colon tumor xenografts. J Interferon Cytokine Res 2001;21(11):885-97
   PubMed Web of Science ®Google Scholar
• Hoving S, Seynhaeve AL, van Tiel ST, Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response. Anticancer Drugs 2006;17(8):949-59
   PubMed Web of Science ®Google Scholar
• Brunstein F, Hoving S, Seynhaeve AL, Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies. J Natl Cancer Inst 2004;96(21):1603-10
   PubMed Web of Science ®Google Scholar
• Hoving S, Brunstein F, aan de Wiel-Ambagtsheer G, Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats. Cancer Res 2005;65(10):4300-8
   PubMed Web of Science ®Google Scholar
• Hayes AJ, Neuhaus SJ, Clark MA, Thomas JM. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma. Ann Surg Oncol 2007;14(1):230-8
   PubMed Web of Science ®Google Scholar
• Grunhagen DJ, de Wilt JH, ten Hagen TL, Eggermont AM. Technology insight: utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nat Clin Pract Oncol 2006;3(2):94-103
   PubMedGoogle Scholar
• Verhoef C, de Wilt JH, Grunhagen DJ, Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma. Curr Treat Options Oncol 2007;8(6):417-27
   PubMedGoogle Scholar
• Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005;5(6):423-35
   PubMed Web of Science ®Google Scholar
• Mitchison T, Kirschner M. Dynamic instability of microtubule growth. Nature 1984;312(5991):237-42
   PubMed Web of Science ®Google Scholar
• Bayless KJ, Davis GE. Microtubule depolymerization rapidly collapses capillary tube networks in vitro and angiogenic vessels in vivo through the small GTPase Rho. J Biol Chem 2004;279(12):11686-95
   PubMed Web of Science ®Google Scholar
• Kanthou C, Tozer GM. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002;99(6):2060-9
   PubMed Web of Science ®Google Scholar
• Kanthou C, Tozer GM. Tumour targeting by microtubule-depolymerizing vascular disrupting agents. Expert Opin Ther Targets 2007;11(11):1443-57
   PubMed Web of Science ®Google Scholar
• Blakey DC, Westwood FR, Walker M, Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 2002;8(6):1974-83
   PubMed Web of Science ®Google Scholar
• Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10(2):415-27
   PubMed Web of Science ®Google Scholar
• Thorpe PE, Chaplin DJ, Blakey DC. The first international conference on vascular targeting: meeting overview. Cancer Res 2003;63(5):1144-7
   PubMedGoogle Scholar
• Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002;53(1):164-71
   PubMed Web of Science ®Google Scholar
• Siemann DW, Rojiani AM. Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002;54(5):1512-17
   PubMed Web of Science ®Google Scholar
• Siemann DW, Mercer E, Lepler S, Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 2002;99(1):1-6
   PubMed Web of Science ®Google Scholar
• Martinelli M, Bonezzi K, Riccardi E, Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. Br J Cancer 2007;97(7):888-94
   PubMed Web of Science ®Google Scholar
• Masunaga S, Sakurai Y, Suzuki M, Combination of the vascular targeting agent ZD6126 with boron neutron capture therapy. Int J Radiat Oncol Biol Phys 2004;60(3):920-7
   PubMed Web of Science ®Google Scholar
• Horsman MR, Murata R. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys 2003;57(4):1047-55
   PubMed Web of Science ®Google Scholar
• Siemann DW, Rojiani AM. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. Int J Radiat Oncol Biol Phys 2005;62(3):846-53
   PubMed Web of Science ®Google Scholar
• Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009;6(8):465-77
   PubMed Web of Science ®Google Scholar
• Beerepoot LV, Radema SA, Witteveen EO, Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 2006;24(10):1491-8
   PubMed Web of Science ®Google Scholar
• Helfrich I, Scheffrahn I, Bartling S, Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med 2010;207(3):491-503
   PubMed Web of Science ®Google Scholar
• Luckner SR, Klotzsche M, Berens C, How an agonist peptide mimics the antibiotic tetracycline to induce Tet-repressor. J Mol Biol 2007;368(3):780-90
   PubMed Web of Science ®Google Scholar
• Herbst RS, Hess KR, Tran HT, Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002;20(18):3792-803
   PubMed Web of Science ®Google Scholar
• Thomas JP, Arzoomanian RZ, Alberti D, Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2003;21(2):223-31
   PubMed Web of Science ®Google Scholar
• Kulke MH, Bergsland EK, Ryan DP, Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 2006;24(22):3555-61
   PubMed Web of Science ®Google Scholar
• Sasaki T, Larsson H, Tisi D, Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity. J Mol Biol 2000;301(5):1179-90
   PubMed Web of Science ®Google Scholar
• Maeshima Y, Colorado PC, Torre A, Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem 2000;275(28):21340-8
   PubMed Web of Science ®Google Scholar
• Lawler J, Detmar M. Tumor progression: the effects of thrombospondin-1 and -2. Int J Biochem Cell Biol 2004;36(6):1038-45
   PubMed Web of Science ®Google Scholar
• Hoekstra R, de Vos FY, Eskens FA, Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. J Clin Oncol 2005;23(22):5188-97
   PubMed Web of Science ®Google Scholar
• Baker LH, Rowinsky EK, Mendelson D, Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. J Clin Oncol 2008;26(34):5583-8
   PubMed Web of Science ®Google Scholar
• Colorado PC, Torre A, Kamphaus G, Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res 2000;60(9):2520-6
   PubMed Web of Science ®Google Scholar
• Kamphaus GD, Colorado PC, Panka DJ, Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 2000;275(2):1209-15
   PubMed Web of Science ®Google Scholar
• Mongiat M, Sweeney SM, San Antonio JD, Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J Biol Chem 2003;278(6):4238-49
   PubMed Web of Science ®Google Scholar
• Strander H. Interferon treatment of human neoplasia. Adv Cancer Res 1986;46:1-265
   PubMedGoogle Scholar
• Dawson DW, Volpert OV, Gillis P, Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999;285(5425):245-8
   PubMed Web of Science ®Google Scholar
• Kurup A, Lin CW, Murry DJ, Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University. Ann Oncol 2006;17(1):97-103
   PubMed Web of Science ®Google Scholar
• O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999;285(5435):1926-8
   PubMed Web of Science ®Google Scholar
• Lee TH, Rhim T, Kim SS. Prothrombin kringle-2 domain has a growth inhibitory activity against basic fibroblast growth factor-stimulated capillary endothelial cells. J Biol Chem 1998;273(44):28805-12
   PubMed Web of Science ®Google Scholar
• Maione TE, Gray GS, Petro J, Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990;247(4938):77-9
   PubMed Web of Science ®Google Scholar
• Hayami T, Shukunami C, Mitsui K, Specific loss of chondromodulin-I gene expression in chondrosarcoma and the suppression of tumor angiogenesis and growth by its recombinant protein in vivo. FEBS Lett 1999;458(3):436-40
   PubMed Web of Science ®Google Scholar
• Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295(5564):2387-92
   PubMed Web of Science ®Google Scholar
• James J, Murry DJ, Treston AM, Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest New Drugs 2007;25(1):41-8
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Richardson PG, Lacy MQ, Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. Clin Cancer Res 2007;13(20):6162-7
   PubMed Web of Science ®Google Scholar
• Pike SE, Yao L, Jones KD, Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 1998;188(12):2349-56
   PubMed Web of Science ®Google Scholar
• Mita MM, Rowinsky EK, Forero L, A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. Cancer Chemother Pharmacol 2007;59(2):165-74
   PubMed Web of Science ®Google Scholar
• Traxler P, Allegrini PR, Brandt R, AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2004;64(14):4931-41
   PubMed Web of Science ®Google Scholar
• Fiedler W, Mesters R, Tinnefeld H, A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 2003;102(8):2763-7
   PubMed Web of Science ®Google Scholar
• Griffioen AW, van der Schaft DW, Barendsz-Janson AF, Anginex, a designed peptide that inhibits angiogenesis. Biochem J 2001;354(Pt 2):233-42
   PubMedGoogle Scholar
• MacDonald TJ, Stewart CF, Kocak M, Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol 2008;26(6):919-24
   PubMed Web of Science ®Google Scholar
• Reardon DA, Fink KL, Mikkelsen T, Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008;26(34):5610-17
   PubMed Web of Science ®Google Scholar
• Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2004;26(7):587-612
   PubMed Web of Science ®Google Scholar
• Cianfrocca ME, Kimmel KA, Gallo J, Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours. Br J Cancer 2006;94(11):1621-6
   PubMed Web of Science ®Google Scholar
• Robertson JD, Botwood NA, Rothenberg ML, Schmoll HJ. Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III. Clin Colorectal Cancer 2009;8(1):59-60
   PubMed Web of Science ®Google Scholar
• Heymach JV, Paz-Ares L, De Braud F, Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008;26(33):5407-15
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Yi J, Ince W, The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 2009;14(1):22-8
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27(8):1227-34
   PubMed Web of Science ®Google Scholar
• Willett CG, Kozin SV, Duda DG, Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice. Semin Oncol 2006;33(5 Suppl 10):S35-40
   PubMed Web of Science ®Google Scholar
• Jayson GC, Mulatero C, Ranson M, Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer. Eur J Cancer 2005;41(4):555-63
   PubMed Web of Science ®Google Scholar
• Posey JA, Ng TC, Yang B, A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res 2003;9(4):1323-32
   PubMed Web of Science ®Google Scholar
• Lau SC, Rosa DD, Jayson G. Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis. Curr Opin Mol Ther 2005;7(5):493-501
   PubMed Web of Science ®Google Scholar
• Cohen EE, Rosen LS, Vokes EE, Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008;26(29):4708-13
   PubMed Web of Science ®Google Scholar
• McNeel DG, Eickhoff J, Lee FT, Phase I trial of a monoclonal antibody specific for alpha-v-beta-3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin Cancer Res 2005;11(21):7851-60
   PubMed Web of Science ®Google Scholar
• Delbaldo C, Raymond E, Vera K, Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alpha-v-beta-3 integrin receptor, in patients with advanced solid tumors. Invest New Drugs 2008;26(1):35-43
   PubMed Web of Science ®Google Scholar
• Mitjans F, Meyer T, Fittschen C, In vivo therapy of malignant melanoma by means of antagonists of alpha-v integrins. Int J Cancer 2000;87(5):716-23
   PubMed Web of Science ®Google Scholar
• Ricart AD, Tolcher AW, Liu G, Volociximab, a chimeric monoclonal antibody that specifically binds alph-5-beta-1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res 2008;14(23):7924-9
   PubMed Web of Science ®Google Scholar
• Ridgway J, Zhang G, Wu Y, Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006;444(7122):1083-7
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24
   PubMed Web of Science ®Google Scholar
• Cherix S, Speiser M, Matter M, Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients. J Surg Oncol 2008;98(3):148-55
   PubMed Web of Science ®Google Scholar
• Rossi CR, Russano F, Mocellin S, TNF-based isolated limb perfusion followed by consolidation biotherapy with systemic low-dose interferon alpha 2b in patients with in-transit melanoma metastases: a pilot trial. Ann Surg Oncol 2008;15(4):1218-23
   PubMed Web of Science ®Google Scholar
• Joensuu H, De Braud F, Coco P, Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Ann Oncol 2008;19(1):173-7
   PubMed Web of Science ®Google Scholar
• Brunstein F, Rens J, van Tiel ST, Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery. Br J Cancer 2006;95(12):1663-9
   PubMed Web of Science ®Google Scholar
• Brunstein F, Eggermont AM, de Wiel-Ambagtsheer G, Synergistic antitumor effects of histamine plus melphalan in isolated hepatic perfusion for liver metastases. Ann Surg Oncol 2007;14(2):795-801
   PubMed Web of Science ®Google Scholar
• Blakey DC, Ashton SE, Westwood FR, ZD6126: a novel small molecule vascular targeting agent. Int J Radiat Oncol Biol Phys 2002;54(5):1497-502
   PubMed Web of Science ®Google Scholar
• LoRusso PM, Gadgeel SM, Wozniak A, Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs 2008;26(2):159-67
   PubMed Web of Science ®Google Scholar
• Rustin GJ, Galbraith SM, Anderson H, Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003;21(15):2815-22
   PubMed Web of Science ®Google Scholar
• Chaplin DJ, Horsman MR, Siemann DW. Current development status of small-molecule vascular disrupting agents. Curr Opin Investig Drugs 2006;7(6):522-8
   PubMed Web of Science ®Google Scholar
• Hori K, Saito S, Sato Y, Differential relationship between changes in tumour size and microcirculatory functions induced by therapy with an antivascular drug and with cytotoxic drugs. implications for the evaluation of therapeutic efficacy of AC7700 (AVE8062). Eur J Cancer 2003;39(13):1957-66
   PubMed Web of Science ®Google Scholar
• Kirwan IG, Loadman PM, Swaine DJ, Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate. Clin Cancer Res 2004;10(4):1446-53
   PubMed Web of Science ®Google Scholar
• McKeage MJ, Von Pawel J, Reck M, Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 2008;99(12):2006-12
   PubMed Web of Science ®Google Scholar
• Rehman F, Rustin G. ASA404: update on drug development. Expert Opin Investig Drugs 2008;17(10):1547-51
   PubMed Web of Science ®Google Scholar
• Cai SX. Small molecule vascular disrupting agents: potential new drugs for cancer treatment. Recent Pat Anticancer Drug Discov 2007;2(1):79-101
   PubMed Web of Science ®Google Scholar
• Fox E, Maris JM, Widemann BC, A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors. Clin Cancer Res 2006;12(16):4882-7
   PubMed Web of Science ®Google Scholar
• Mauer AM, Cohen EE, Ma PC, A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. J Thorac Oncol 2008;3(6):631-6
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Andoh M, Kawahara M, Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks. Cancer Sci 2009;100(2):316-21
   PubMed Web of Science ®Google Scholar
• Patel S, Keohan ML, Saif MW, Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy. Cancer 2006;107(12):2881-7
   PubMed Web of Science ®Google Scholar
• Brooks PC, Silletti S, von Schalscha TL, Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998;92(3):391-400
   PubMed Web of Science ®Google Scholar
• Corbacho AM, Martinez De La Escalera G, Clapp C. Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J Endocrinol 2002;173(2):219-38
   PubMed Web of Science ®Google Scholar
• Moses MA, Wiederschain D, Wu I, Troponin I is present in human cartilage and inhibits angiogenesis. Proc Natl Acad Sci USA 1999;96(6):2645-50
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Sorensen AG, di Tomaso E, AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11(1):83-95
   PubMed Web of Science ®Google Scholar
• Strumberg D, Schultheis B, Adamietz IA, Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours. Br J Cancer 2008;99(10):1579-85
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10(1):25-34
   PubMed Web of Science ®Google Scholar
• Seynhaeve AL, de Wilt JH, van Tiel ST, Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity. Br J Cancer 2002;86(7):1174-9
   PubMed Web of Science ®Google Scholar
• ten Hagen TL, Hoving S, Ambagtsheer G, Lack of efficacy of Doxil in TNF-alpha-based isolated limb perfusion in sarcoma-bearing rats. Br J Cancer 2004;90(9):1830-2
   PubMed Web of Science ®Google Scholar
• van Ijken MG, van Etten B, de Wilt JH, Tumor necrosis factor-alpha augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model. J Immunother 2000;23(4):449-55
   PubMed Web of Science ®Google Scholar
• Tomazic VJ, Farha M, Loftus A, Elias EG. Anti-tumor activity of recombinant tumor necrosis factor on mouse fibrosarcoma in vivo and in vitro. J Immunol 1988;140(11):4056-61
   PubMed Web of Science ®Google Scholar
• Brouckaert P, Takahashi N, van Tiel ST, Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics. Int J Cancer 2004;109(3):442-8
   PubMed Web of Science ®Google Scholar
• Hoving S, Seynhaeve AL, van Tiel ST, Addition of low-dose tumor necrosis factor-alpha to systemic treatment with STEALTH liposomal doxorubicin (Doxil) improved anti-tumor activity in osteosarcoma-bearing rats. Anticancer Drugs 2005;16(6):667-74
   PubMed Web of Science ®Google Scholar
• Krosnick JA, Mule JJ, McIntosh JK, Rosenberg SA. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo. Cancer Res 1989;49(14):3729-33
   PubMed Web of Science ®Google Scholar
• Suzuki S, Ohta S, Takashio K, Augmentation for intratumoral accumulation and anti-tumor activity of liposome-encapsulated adriamycin by tumor necrosis factor-alpha in mice. Int J Cancer 1990;46(6):1095-100
   PubMed Web of Science ®Google Scholar
• Hoving S, van Tiel ST, Eggermont AM, ten Hagen TL. Effect of low-dose tumor necrosis factor-alpha in combination with STEALTH liposomal cisplatin (SPI-077) on soft-tissue- and osteosarcoma-bearing rats. Anticancer Res 2005;25(2A):743-50
   PubMed Web of Science ®Google Scholar
• ten Hagen TL, Seynhaeve AL, van Tiel ST, Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats. Int J Cancer 2002;97(1):115-20
   PubMed Web of Science ®Google Scholar
• Saito M, Fan D, Lachman LB. Antitumor effects of liposomal IL1 alpha and TNF alpha against the pulmonary metastases of the B16F10 murine melanoma in syngeneic mice. Clin Exp Metastasis 1995;13(4):249-59
   PubMed Web of Science ®Google Scholar
• Curnis F, Sacchi A, Borgna L, Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000;18(11):1185-90
   PubMed Web of Science ®Google Scholar
• Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2002;110(4):475-82
   PubMed Web of Science ®Google Scholar
• Crippa L, Gasparri A, Sacchi A, Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha. Cancer Res 2008;68(4):1154-61
   PubMed Web of Science ®Google Scholar
• Curnis F, Gasparri A, Sacchi A, Coupling tumor necrosis factor-alpha with alpha-V integrin ligands improves its antineoplastic activity. Cancer Res 2004;64(2):565-71
   PubMed Web of Science ®Google Scholar
• Nicholson B, Lloyd GK, Miller BR, NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs 2006;17(1):25-31
   PubMed Web of Science ®Google Scholar
• Kasibhatla S, Baichwal V, Cai SX, MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. Cancer Res 2007;67(12):5865-71
   PubMed Web of Science ®Google Scholar